Skip to main content

Table 3 Hematological and non-hematological adverse events (n = 234)

From: Association of nutritional status-related indices and chemotherapy-induced adverse events in gastric cancer patients

Events Grade of chemotherapy toxicity (No (%))
Grade 0 Grade 1 Grade 2 Grade 3 Grade 4 Grade 3 + 4 (%)
Hematological adverse events Anemia 29(12.4) 153(65.4) 45(19.2) 7(3.0) 3
Neutropenia 94(40.2) 41(17.5) 67(28.6) 31(13.2) 1(0.4) 13.6
Thrombocytopenia 150(64.1) 73(31.2) 10(4.3) 1(0.4) 0.4
Febrile neutropenia 233(99.6) 1(0.4) 0.4
Leucopenia 125(53.4) 86(36.8) 22(9.4) 1(0.4) 0.4
Total 14(6.0) 95(40.6) 87(37.2) 37(15.8) 1(0.4) 16.2
Non-hematological adverse events Anorexia 142(60.7) 61(26.1) 28(12.0) 3(1.3) 1.3
Nausea 165(70.5) 51(21.8) 17(7.3) 1(0.4) 0.4
Vomiting 206(88.0) 16(6.8) 11(4.7) 1(0.4) 0.4
Diarrhea 119(50.9) 58(24.8) 43(18.4) 14(6.0) 6
Constipation 213(91.0) 19(8.1) 2(0.9) 0
Abdominal pain 183(78.2) 31(13.2) 10(4.3) 10(4.3) 4.3
Stomatitis 191(81.6) 26(11.1) 15(6.4) 2(0.9) 0.9
Hand-foot syndrome 200(85.5) 27(11.5) 6(2.6) 1(0.4) 0.4
Fatigue 194(82.9) 35(15.0) 4(1.7) 1(0.4) 0.4
Hyperpigmentation 183(78.2) 47(20.1) 3(1.3) 1(0.4) 0.4
Rash 215(91.9) 14(6.0) 3 (1.3) 2(0.9) 0.8
Elevated AST/ALT level 149(63.7) 77(32.9) 5(2.1) 3(1.3) 1.3
Elevated bilirubin level 89(38.0) 99(42.3) 43(18.4) 3(1.3) 1.3
Elevated creatinine level 230(98.3) 4(1.7) 0
Total 10(4.3) 99(23.1) 86(36.8) 39(16.7) 16.7
  1. AST/ALT aspartate transaminase/alanine transaminase